GCORE
Gcore, the global edge AI, cloud, network, and security solutions provider, today announced the acquisition of StackPath’s web application and API protection (WAAP) solution. A highly regarded security product for protecting applications, the new acquisition will provide Gcore customers with an enhanced, enterprise-grade security solution, incorporating web application firewall (WAF), API security, bot protection, and Layer-7 DDoS mitigation at the edge.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240306076612/en/
Gcore is the global edge AI, cloud, network, and security solutions provider. (Graphic: Gcore)
The acquisition marks a pivotal advancement in Gcore’s mission to deliver comprehensive, edge security services to its customers worldwide. The WAAP will be integrated into Gcore’s security product lineup by Q3 2024.
StackPath WAAP was recognised as a cloud WAF leader by independent security solutions assessor, SecureIQLab in a report comparing the security and operational efficiency of multiple cloud WAF solutions.
Andre Reitenbach, CEO at Gcore, comments: “The acquisition of StackPath WAAP marks a significant milestone in our strategic roadmap, underscoring our commitment to continuous innovation of our solutions and edge infrastructure. With its outstanding reputation for quality, StackPath WAAP stands as a premier solution in the market. Its integration will further strengthen our customers’ application and API security and provide them with enhanced defences against application-layer DDoS attacks at the edge”.
Gcore’s extensive edge network spans over 160 points of presence, delivering fast, reliable, and secure digital experiences worldwide. By leveraging its edge network, Gcore brings protection closer to the end user. This approach reduces latency, scales seamlessly against large-scale DDoS attacks, protects against common vulnerabilities, safeguards critical API endpoints, and leverages real-time threat intelligence. A key advantage of StackPath WAAP is its ability to leverage machine learning to detect and mitigate malicious behaviour. As Gcore incorporates the product into its portfolio, it will enhance its capabilities with AI-driven WAF, enabling advanced identification of HTTP patterns to provide enhanced protection and improve mitigation for zero-day attacks.
Gcore will maintain the rapid setup and out-of-the-box features that have made StackPath WAAP easily configurable, and add capabilities including customisation, advanced threat identification, and real-time analytics. Integration is scheduled by Q3 2024, with an early-access version available for customer evaluation in the meantime. Flexible pricing plans will meet the needs of customers based on usage.
“We’re passionate about security in the cloud and proud of the WAAP we built at StackPath,” said Kip Turco, Chief Executive Officer for StackPath. “When we decided to focus even more specifically on our latency-sensitive, highly distributed edge-computing platform, we knew Gcore would be the perfect home for the continuing innovation of this next-gen WAAP. We look forward to partnering with Gcore even more in the ongoing evolution of cloud, edge, and the security solutions the industry needs.”
About Gcore
Gcore is a global edge AI, cloud, network, and security solutions provider. Headquartered in Luxembourg, Gcore manages its own IT infrastructure across six continents, with leading network performance in Europe, Africa, and LATAM.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306076612/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release
Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release
Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press release
A R$490 million investment expands the supply of raw material used in the production of absorbent items Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
